tiprankstipranks
Trending News
More News >
Werewolf Therapeutics (HOWL)
NASDAQ:HOWL
US Market
Advertisement

Werewolf Therapeutics (HOWL) AI Stock Analysis

Compare
664 Followers

Top Page

HOWL

Werewolf Therapeutics

(NASDAQ:HOWL)

Rating:45Neutral
Price Target:
$1.50
▲(7.91%Upside)
Werewolf Therapeutics' overall score is driven by poor financial performance and valuation risks. Despite some technical momentum, the Nasdaq deficiency notice and ongoing financial losses pose significant challenges. Investors should be cautious given the current financial instability and potential listing risks.
Positive Factors
Financial Stability
The company ended the quarter with approximately $122.8 million in cash, expected to fund operations until 2Q26, indicating strong financial stability.
Investment Opportunity
Werewolf represents an interesting investment opportunity with a partnership with Jazz Pharmaceuticals and a cash position of $122.8MM.
Strategic Expansion
Werewolf's strategic expansion of their PREDATOR masking platform to CD3 T-cell engagers is supported by robust clinical validation and industry interest.
Negative Factors
Clinical Uncertainty
There is uncertainty whether the outcomes of WTX-124’s monotherapy and combination trials will be robust enough to engage an investor base generally disinterested in novel cytokine programs.
Revenue Performance
Werewolf reported no revenues for 4Q24 as expected, and R&D expenses were higher than estimated.
Strategic Direction
It is unlikely that the new strategic direction with TCE platform will result in significant appreciation for HOWL in the near-term due to its nascent development stage.

Werewolf Therapeutics (HOWL) vs. SPDR S&P 500 ETF (SPY)

Werewolf Therapeutics Business Overview & Revenue Model

Company DescriptionWerewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
How the Company Makes MoneyWerewolf Therapeutics makes money primarily through the development and commercialization of its proprietary cancer immunotherapies. The company's revenue model includes licensing agreements, partnerships with other pharmaceutical companies, and potential sales of its therapeutics upon successful clinical development and regulatory approval. Key revenue streams are expected to come from milestone payments, royalties on sales, and potentially direct sales of its products. Strategic partnerships and collaborations play a significant role in supporting research and development activities, providing necessary funding and resources to advance its pipeline of therapeutic candidates.

Werewolf Therapeutics Financial Statement Overview

Summary
Werewolf Therapeutics is experiencing significant financial challenges, including ongoing operating losses and negative cash flows. The reliance on external financing indicates potential liquidity risks, and inconsistent revenue growth along with declining equity present challenges for future stability.
Income Statement
35
Negative
Werewolf Therapeutics has shown inconsistent revenue figures over the years with a recent drop from 2023 to 2024. Gross profit margins are highly volatile, and the company has been operating with negative net profit margins consistently, indicating ongoing losses. EBIT and EBITDA margins are negative, reflecting operating inefficiencies and high operational costs relative to revenue.
Balance Sheet
40
Negative
The company has a moderate debt-to-equity ratio, which has improved over time due to a reduction in total debt. However, the equity ratio has been declining, indicating a decrease in equity relative to assets. Return on equity is negative, as losses have been persistent. The financial stability is moderate with a reasonable cash position compared to liabilities, yet the trend is concerning with shrinking equity.
Cash Flow
30
Negative
Operating cash flows have been negative, indicating cash burn, and free cash flows have also been consistently negative, showing challenges in generating cash from operations. Financing cash flows have been positive, suggesting reliance on external financing to support operations. The ratios of cash flows to net income highlight issues in converting revenue into cash.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.89M19.94M16.40M0.000.00
Gross Profit71.00K-18.96M13.89M-735.00K-777.00K
EBITDA-64.05M-32.47M-51.30M-49.25M-14.26M
Net Income-70.52M-37.37M-51.56M-49.77M-14.94M
Balance Sheet
Total Assets126.93M174.83M160.25M179.25M96.40M
Cash, Cash Equivalents and Short-Term Investments111.00M134.34M129.31M157.53M92.57M
Total Debt37.09M51.92M14.68M15.66M2.54M
Total Liabilities53.54M63.46M37.91M26.46M148.26M
Stockholders Equity73.39M111.37M122.34M152.79M-51.86M
Cash Flow
Free Cash Flow-56.44M-33.38M-44.21M-43.37M-19.18M
Operating Cash Flow-56.19M-32.61M-40.60M-42.88M-18.62M
Investing Cash Flow-254.00K-769.00K-3.61M-498.00K-560.00K
Financing Cash Flow13.08M58.43M15.91M109.43M93.86M

Werewolf Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.39
Price Trends
50DMA
1.20
Positive
100DMA
1.09
Positive
200DMA
1.44
Negative
Market Momentum
MACD
0.06
Negative
RSI
64.70
Neutral
STOCH
76.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOWL, the sentiment is Positive. The current price of 1.39 is above the 20-day moving average (MA) of 1.20, above the 50-day MA of 1.20, and below the 200-day MA of 1.44, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 64.70 is Neutral, neither overbought nor oversold. The STOCH value of 76.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HOWL.

Werewolf Therapeutics Risk Analysis

Werewolf Therapeutics disclosed 84 risk factors in its most recent earnings report. Werewolf Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Werewolf Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
¥351.06B11.13-2.99%2.50%11.77%-10.16%
51
Neutral
$83.31M1063.61%475.53%89.94%
45
Neutral
$62.37M-82.81%-92.95%-50.02%
45
Neutral
$59.10M108.28%41.01%
44
Neutral
$41.99M41.08%1.19%61.65%
44
Neutral
$8.68M0.67121.75%
$34.07M
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HOWL
Werewolf Therapeutics
1.37
-1.36
-49.82%
KPTI
Karyopharm Therapeutics
4.43
-10.13
-69.57%
ATRA
Atara Biotherapeutics
12.23
2.06
20.26%
XFOR
X4 Pharmaceuticals
1.50
-24.36
-94.20%
NRXP
NRX Pharmaceuticals
2.99
0.58
24.07%
CAMP
CAMP4 Therapeutics Corporation
1.69
-8.06
-82.67%

Werewolf Therapeutics Corporate Events

Executive/Board ChangesShareholder Meetings
Werewolf Therapeutics Adopts New Bylaws and Elects Directors
Neutral
Jun 13, 2025

On June 12, 2025, Werewolf Therapeutics, Inc. adopted new bylaws to clarify procedural mechanics for stockholder nominations and proposals, specify meeting presiders, and make administrative updates. During the same annual meeting, stockholders elected three directors for three-year terms and ratified Ernst & Young LLP as the independent accounting firm for 2025.

The most recent analyst rating on (HOWL) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Werewolf Therapeutics stock, see the HOWL Stock Forecast page.

Delistings and Listing ChangesRegulatory Filings and Compliance
Werewolf Therapeutics Receives Nasdaq Deficiency Notice
Negative
May 15, 2025

On May 13, 2025, Werewolf Therapeutics received a deficiency letter from Nasdaq indicating that its stock price had fallen below the minimum bid requirement of $1.00 for 30 consecutive business days. This notice does not immediately affect the company’s listing, but Werewolf has 180 days to regain compliance by raising its stock price above $1.00 for at least 10 consecutive days. If unsuccessful, the company may seek an additional compliance period by transferring its listing to the Nasdaq Capital Market, though this involves meeting other criteria and paying a fee. Werewolf is actively monitoring its stock price and exploring options to address the deficiency, but there is no guarantee of success.

The most recent analyst rating on (HOWL) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Werewolf Therapeutics stock, see the HOWL Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
Werewolf Therapeutics Announces Q1 2025 Financial Results
Positive
May 8, 2025

On May 8, 2025, Werewolf Therapeutics announced its first quarter 2025 financial results and business updates, highlighting significant progress in its clinical programs. The company is on track with its WTX-124 Phase 1/1b trial, expecting data readouts and FDA interactions later in the year, and has initiated a Phase 1b/2 trial for WTX-330. Werewolf is also advancing its INDUCER T cell engager molecules, with a development candidate expected by mid-2025, and maintains a cash runway into the fourth quarter of 2026.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 16, 2025